Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.62 -1.3%	$2.66	$1.20 ▼ $6.75	$148.89M	2.87	1.98 million shs	348,118 shs
HURA TuHURA Biosciences	$2.97 -1.0%	$2.59	$1.80 ▼ $8.40	$148.65M	0.04	306,995 shs	92,743 shs
NKTX Nkarta	$2.27 -1.5%	$1.95	$1.31 ▼ $6.63	$160.87M	0.72	950,447 shs	281,698 shs
SNYR Synergy CHC	$2.95 -10.1%	$3.19	$1.19 ▼ $10.00	$27.85M	N/A	465,426 shs	50,059 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-3.64%	+4.33%	-15.34%	+30.54%	-53.91%
HURA TuHURA Biosciences	-2.91%	-7.69%	+14.50%	-9.37%	+299,999,900.00%
NKTX Nkarta	-2.13%	+17.35%	+20.42%	+35.29%	-55.85%
SNYR Synergy CHC	-5.75%	-16.33%	-9.14%	+56.19%	+10,833.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.2927 of 5 stars	3.6	1.0	3.8	1.7	1.9
HURA TuHURA Biosciences	1.5939 of 5 stars	3.7	0.0	2.2	0.0	0.0
NKTX Nkarta	2.026 of 5 stars	3.5	0.0	3.0	1.7	0.6
SNYR Synergy CHC	4.3491 of 5 stars	3.8	0.0	3.0	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.17	Buy	$12.40	360.97% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	326.49% Upside
NKTX Nkarta	3.00	Buy	$13.60	491.56% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	204.88% Upside

Current Analyst Ratings Breakdown

Latest SNYR, BDTX, HURA, and NKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
8/13/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/11/2025	BDTX Black Diamond Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	$70M	2.19	N/A	N/A	$2.33 per share	1.15
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.38 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.04 per share	N/A
SNYR Synergy CHC	$34.83M	0.89	$0.25 per share	13.08	($1.31) per share	-2.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.23	11.72	N/A	N/A	N/A	12.70%	9.58%	11/4/2025 (Estimated)
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	-248.79%	-150.83%	10/6/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.48	N/A	N/A	N/A	N/A	-27.74%	-22.38%	11/6/2025 (Estimated)
SNYR Synergy CHC	$2.12M	$0.38	8.63	5.56	N/A	10.02%	-18.56%	20.28%	N/A

Latest SNYR, BDTX, HURA, and NKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
8/14/2025	Q2 2025	SNYR Synergy CHC	$0.08	$0.17	+$0.09	$0.17	$10.80 million	$6.74 million
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	-$0.31	+$0.06	-$0.31	N/A	N/A
8/7/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.25	-$0.19	+$0.06	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	8.73	8.73
HURA TuHURA Biosciences	N/A	0.83	3.00
NKTX Nkarta	N/A	15.67	15.67
SNYR Synergy CHC	N/A	2.74	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
HURA TuHURA Biosciences	0.62%
NKTX Nkarta	80.54%
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
HURA TuHURA Biosciences	0.20%
NKTX Nkarta	8.40%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.94 million	53.54 million	Optionable
HURA TuHURA Biosciences	N/A	50.05 million	43.59 million	N/A
NKTX Nkarta	140	71.03 million	65.06 million	Optionable
SNYR Synergy CHC	40	9.44 million	4.10 million	N/A

SNYR, BDTX, HURA, and NKTX Headlines

Recent News About These Companies

Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy

August 18 at 1:09 PM | taiwannews.com.twT

New to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...

August 18 at 1:09 PM | finanznachrichten.de

Synergy CHC announces major distribution with for FOCUSfactor Focus + Energy

August 18 at 1:09 PM | msn.com

Synergy CHC Expands FOCUSfactor Distribution with EG America

August 18 at 9:59 AM | tipranks.com

Analysts Set Expectations for Synergy CHC FY2025 Earnings

August 18 at 3:01 AM | americanbankingnews.com

Synergy CHC files to sell 1.28M shares of common stock

August 15, 2025 | msn.com

Synergy Chc EPS Jumps 86 Percent in Q2

August 15, 2025 | theglobeandmail.com

Synergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | finanznachrichten.de

Synergy CHC reports Q2 EPS 17c vs 9c last year

August 14, 2025 | msn.com

Synergy CHC Corp. Reports Strong Second Quarter 2025 Financial Results with Significant Year-over-Year Growth

August 14, 2025 | quiverquant.comQ

Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | globenewswire.com

Head-To-Head Contrast: Synergy CHC (NASDAQ:SNYR) vs. Krispy Kreme (NASDAQ:DNUT)

August 10, 2025 | americanbankingnews.com

New to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion Rate

August 5, 2025 | indystar.comI

New to The Street Launches 1,000+ Commercial TV Blitz for Synergy CHC ($SNYR), Makers of Focus Factor(R) – Adds NewsOut Video PR Coverage & NYC #1 Market Saturation

August 5, 2025 | desmoinesregister.comD

Jack Ross Buys Handful Of Shares In Synergy CHC

August 3, 2025 | finance.yahoo.com

Insider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of Stock

August 1, 2025 | insidertrades.com

Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

July 31, 2025 | manilatimes.netM

Synergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution Expansion

July 31, 2025 | quiverquant.comQ

Synergy CHC Expands Retail Presence in North America

June 30, 2025 | tipranks.com

Synergy CHC Corp. (SNYR) Stock Price Today - WSJ

June 24, 2025 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR, BDTX, HURA, and NKTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.62 -0.04 (-1.32%)

As of 02:45 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

TuHURA Biosciences NASDAQ:HURA

$2.97 -0.03 (-1.03%)

As of 02:45 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Nkarta NASDAQ:NKTX

$2.26 -0.04 (-1.52%)

As of 02:45 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Synergy CHC NASDAQ:SNYR

$2.95 -0.33 (-10.06%)

As of 02:12 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time